Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4-Reference-Cited by-同舟云学术

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4

Published:2020-04-27 Issue:6 Volume:15 Page:1306-1312
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Maneiro Marı́a¹^ORCID,Forte Nafsika²^ORCID,Shchepinova Maria M.¹^ORCID,Kounde Cyrille S.¹^ORCID,Chudasama Vijay²^ORCID,Baker James Richard²^ORCID,Tate Edward W.¹^ORCID

Affiliation:

1. Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom

2. Department of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, United Kingdom

Funder

Engineering and Physical Sciences Research Council

Xunta de Galicia

GlaxoSmithKline

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acschembio.0c00285

Reference48 articles.

1. Selective degradation of splicing factor CAPERα by anticancer sulfonamides

2. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

3. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15

4. Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820

5. Small molecule-mediated protein knockdown as a new approach to drug discovery

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. PROTAC technology: From drug development to probe technology for target deconvolution;European Journal of Medicinal Chemistry;2024-10

3. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

4. A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy;Nano Research;2024-09-07

5. M1/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis;Life Sciences;2024-09